Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2021-11-22 Capital/Financing Update
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Non-Renounceable Rights Issue Opens 9 pages 704.8KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Living Cell Technologies Limited regarding the opening of a non-renounceable rights issue to raise capital. It details the offer terms, timetable, instructions for shareholders, and contact information. The content focuses on fundraising activities, share subscription rights, and related procedural information. There are no financial statements, audit opinions, management discussions of financial results, or regulatory certifications present. The document is not a full financial report but an update on capital raising activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the rights issue, not merely a brief notice or a report publication announcement.
2021-11-22 English
LCT- Rights Issue 3 pages 448.6KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement from Living Cell Technologies Limited regarding a pro rata renounceable rights issue, detailing the terms, timetable, and expected proceeds of the rights issue. It includes information about the offer, record date, closing date, and allotment of securities. The content focuses on capital raising activities and financing updates rather than financial results, management changes, or regulatory filings. The document length is about 5965 characters, which is sufficient to contain substantive information about the rights issue. Therefore, this document fits the category of Capital/Financing Update (CAP).
2021-11-14 English
Prospectus- Rights Issue 32 pages 960.0KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Rights Issue Prospectus' and details a pro rata renounceable rights issue offering new shares and options to existing shareholders. It includes important dates related to the offer, terms of the rights issue, risk factors, and a chairman's letter encouraging participation. The content focuses on raising capital through a rights issue, describing the offer, its purpose, and associated risks. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report but the actual prospectus for the rights issue, and it is substantive and detailed, not a brief announcement or regulatory filing. Therefore, the correct classification is CAP with high confidence.
2021-11-14 English
Proposed issue of securities - LCT 8 pages 36.9KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Living Cell Technologies Limited regarding a proposed issue of securities, specifically a standard pro rata issue including rights issue options and ordinary fully paid shares. It includes details such as offer price, record date, issue date, and terms of the securities. The document is structured as an announcement to the ASX (Australian Securities Exchange) and contains no financial statements or detailed financial analysis. It is not a full financial report but rather a disclosure about capital raising activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2021-11-14 English
Update - Proposed issue of securities - LCT 8 pages 36.6KB
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding a proposed issue of securities by Living Cell Technologies Limited. It includes specifics about the type of securities, offer price, issue ratios, timetable, fees, and other related information. The content is consistent with disclosures required for capital raising activities, such as rights issues and options issuance. There is no indication that this is a full financial report, audit report, or earnings release. It is not a regulatory filing of miscellaneous nature, but a focused update on financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication announcement, but a substantive update on capital raising.
2021-11-14 English
Chairman's Address to the 2021 Annual General Meeting 4 pages 160.9KB
AGM Information Classification · 95% confidence The document is titled 'Chairman’s Address to the 2021 Annual General Meeting' and contains a speech by the Interim Executive Chairman addressing shareholders. It discusses company activities over the past year, fundraising efforts, clinical trials, board updates including the passing of a founding director and retirement of the CEO, and thanks to staff and shareholders. The content is typical of presentations or speeches given at an AGM rather than a formal annual report or financial statement. The length is about 6,700 characters, which is consistent with a detailed AGM address but not a full annual report. There is no detailed financial data or comprehensive financial performance analysis present. Therefore, this document fits best as AGM Information (AGM-R).
2021-11-10 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.